[Correspondence] Crossing the regulatory and clinical operational valley in antimicrobial resistance: from a start-up's perspective | ClinicLens
The milestone that gave me the greatest satisfaction last year was not a headline-grabbing breakthrough, but the quiet alignment of two parallel worlds: regulatory clearance and operational readiness for BWC0977, a novel dual-targeting inhibitor of DNA gyrase and topoisomerase IV
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.